The Center
Multiple Sclerosis Center Dresden
Patient Information
Contact MSC
Physicians & Nurses
Study Team
Neuropsychology
Mobility Center
The Mobility Center
Walking Assessment
Jump Assessment
DIERS
EMIQ
Projects
Neuroimmunological Laboratory
The NIL
Neurofilament light chain
Autonomic & Neuroendocrinological Functional Laboratory
The ANF
ANF Assessment
MS Living Lab
Management & Science
Team Management & Science
Projects
eHealth & Analytics
MSDS 3D
MSDS Clinic & Practice
MS-HRS
MTRS
Multiple Sclerosis Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
MS Tag 2025
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Spenden
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Neurovision
Immune cell calender 25
Sherlock-MS-Blog
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
English
Deutsch
English
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
NIL
Jahr
Publikationsjahr
2021
Autoren
Autorenliste der Publikation
Proschmann U, Haase R, Inojosa H, Akgün K, Ziemssen T.
Verlag
Publisher-Information
Front Immunol 2021;12.
Link
Zur Publikation (externer Server)
https://doi.org/10.3389/fimmu.2021.715195
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Neuroimmunologie
Treatments
NIL
2021
A Review of the Impact of Platform Therapies (DMTs) on Associated Clinical Symptoms of Multiple Sclerosis
MS Treatments
Jahr
2025
Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis
NIL
Jahr
2025
Whole brain volume loss is associated with a short-term disability progression in relapse-activity free multiple sclerosis
Multiple Sclerosis
Jahr
2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment Response
NIL
Jahr
2025
Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing.
MS Treatments
Jahr
2025
